Last update 26 Dec 2024
Tinlorafenib
Last update 26 Dec 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms ARRY 461, ARRY461, PF-07284890 |
Target |
Mechanism BRAF inhibitors(Serine/threonine-protein kinase B-raf inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure
Molecular FormulaC19H19ClF2N4O3S |
InChIKeyVVLVISDSGRHLMB-UHFFFAOYSA-N |
CAS Registry2573781-75-4 |
Related
2
Clinical Trials associated with TinlorafenibA PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE DOSE, 2-SEQUENCE, 3 PERIOD CROSSOVER STUDY TO EVALUATE THE EFFECT OF A LOW-FAT AND HIGH-FAT MEAL ON THE RELATIVE BIOAVAILABILITY OF PF-07284890 IN HEALTHY ADULT PARTICIPANTS
A TWO-PART, PHASE 1A/B, OPEN-LABEL, MULTICENTER TRIAL EVALUATING PHARMACOKINETICS, SAFETY AND EFFICACY OF PF 07284890 (ARRY 461) IN PARTICIPANTS WITH BRAF V600 MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT
100 Clinical Results associated with Tinlorafenib
Login to view more data
100 Translational Medicine associated with Tinlorafenib
Login to view more data
100 Patents (Medical) associated with Tinlorafenib
Login to view more data
100 Deals associated with Tinlorafenib
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| BRAF V600 mutation-positive Melanoma | Phase 1 | US | 08 Jan 2021 | |
| BRAF V600 mutation-positive Melanoma | Phase 1 | CA | 08 Jan 2021 | |
| BRAF V600 mutation-positive Melanoma | Phase 1 | IL | 08 Jan 2021 | |
| BRAF V600 mutation-positive Neoplasms | Phase 1 | US | 08 Jan 2021 | |
| BRAF V600 mutation-positive Neoplasms | Phase 1 | CA | 08 Jan 2021 | |
| BRAF V600 mutation-positive Neoplasms | Phase 1 | IL | 08 Jan 2021 | |
| Brain Cancer | Phase 1 | US | 08 Jan 2021 | |
| Brain Cancer | Phase 1 | CA | 08 Jan 2021 | |
| Brain Cancer | Phase 1 | IL | 08 Jan 2021 | |
| Non-Small Cell Lung Cancer | Phase 1 | US | 08 Jan 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free